Company Profile
Northwest Biotherapeutics Stock Price, News & Analysis
- Ticker:
- NWBO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.18 USD (+8.84%)
Close
Last updated: August 6, 2026
—
Market cap
Why the stock is moving
As of Aug 6, 2026, NWBO closed up 8.84% at $0.1785. No new same-company headline was identified in the current news window.
Company overview
Business overview
Northwest Biotherapeutics is an immunotherapy company focused on cancer vaccines and personalized tumor treatment. Its business has been shaped by a long-duration and highly controversial development story.
Geographic Base and Sector Classification
Headquartered in the United States and listed on OTC markets, Northwest sits in oncology biotechnology.
Business Model Characteristics
The company depends on clinical validation, regulatory progress, and the ability to convert vaccine science into value.
Position Within the Biotechnology Landscape
Northwest is a highly speculative oncology name whose valuation is driven by high-uncertainty clinical outcomes.
Future catalysts
Northwest Biotherapeutics’s catalyst is DCVax-L and any regulatory or commercial update that clarifies whether the long-running glioblastoma story still has a path. The stock remains heavily event-driven.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Northwest Biotherapeutics (NWBO)?
Northwest Biotherapeutics (NWBO) most recently closed at 0.18 USD, a +8.84% move versus the previous session.
What does Northwest Biotherapeutics do?
Northwest Biotherapeutics is an immunotherapy company focused on cancer vaccines and personalized tumor treatment. Its business has been shaped by a long-duration and highly controversial development story.
On which exchange is NWBO stock listed?
Northwest Biotherapeutics (NWBO) is associated with NASDAQ, United States, Biopharma.
What is Northwest?
Northwest Biotherapeutics’s catalyst is DCVax-L and any regulatory or commercial update that clarifies whether the long-running glioblastoma story still has a path.
Which conditions is Northwest Biotherapeutics targeting with Northwest?
Northwest Biotherapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Northwest Biotherapeutics describe recent progress with Northwest?
Northwest Biotherapeutics’s catalyst is DCVax-L and any regulatory or commercial update that clarifies whether the long-running glioblastoma story still has a path.
What is Biotherapeutics?
Northwest Biotherapeutics is an immunotherapy company focused on cancer vaccines and personalized tumor treatment.
What should investors watch for with Biotherapeutics?
Northwest Biotherapeutics’s catalyst is DCVax-L and any regulatory or commercial update that clarifies whether the long-running glioblastoma story still has a path.